ArticleDiscover oncology2025
KLB as a potential prognostic biomarker and therapeutic target in colorectal cancer: insights from multi omics and single cell analyses.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Colitis-Associated Colorectal Cancer-STAT3 Inhibition as a Preventive Strategy.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is one of the most common gastrointestinal malignancies, with a rising global incidence. Despite advances in diagnosis and treatment, effective biomarkers for early detection and targeted therapy remain limited. β-Klotho (KLB), a co-receptor in the FGF signaling pathway, has been implicated in tumor progression and poor prognosis in several cancers. However, its role in CRC is still poorly understood.
methodsTo investigate the function of KLB in CRC, we performed a comprehensive pan-cancer analysis using datasets from TCGA, GTEx, Human Protein Atlas, cBioPortal, UALCAN, and TIMER2.0. Analyses included KLB expression profiles, promoter methylation, genetic alterations, immune checkpoint associations, and immune cell infiltration. Functional enrichment was conducted via GO/KEGG and GSEA. A prognostic model was constructed using biostatistical methods. In vitro and in vivo assays-including CCK-8, colony formation, wound healing, and subcutaneous tumor formation in mice-were conducted to evaluate the biological effects of KLB on CRC cells. Additionally, single-cell RNA sequencing data were analyzed to explore the cell-type-specific expression of KLB within the tumor microenvironment.
resultsKLB expression was significantly downregulated in CRC tissues compared to normal tissues and negatively correlated with TNM stage and overall prognosis. Promoter methylation and somatic mutations were observed in CRC, suggesting epigenetic and genetic regulation of KLB. Functional enrichment revealed that KLB is involved in regulating the cell cycle, chromatin remodeling, and immune responses. The prognostic nomogram based on KLB expression showed improved predictive performance for progression-free interval (C-index = 0.778). Experimentally, KLB overexpression inhibited CRC cell proliferation and migration. Single-cell RNA-seq analysis demonstrated that KLB is primarily expressed in fibroblasts and stromal cells within the CRC tumor microenvironment, implicating its role in intercellular communication and immune modulation through pathways such as MIF and MK signaling.
conclusionKLB functions as a potential tumor suppressor in CRC, with diagnostic, prognostic, and therapeutic implications. Its expression in stromal components of the tumor microenvironment suggests a regulatory role in immune response and tumor progression. These findings support KLB as a promising biomarker and therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.